<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38452856</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1995-820X</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Virologica Sinica</Title><ISOAbbreviation>Virol Sin</ISOAbbreviation></Journal><ArticleTitle>Identification of fangchinoline as a broad-spectrum enterovirus inhibitor through reporter virus based high-content screening.</ArticleTitle><Pagination><StartPage>301</StartPage><EndPage>308</EndPage><MedlinePgn>301-308</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virs.2024.02.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1995-820X(24)00026-9</ELocationID><Abstract><AbstractText>Hand, foot, and mouth disease (HFMD) is a common pediatric illness mainly caused by enteroviruses, which are important human pathogens. Currently, there are no available antiviral agents for the therapy of enterovirus infection. In this study, an excellent high-content antiviral screening system utilizing the EV-A71-eGFP reporter virus was developed. Using this screening system, we screened a drug library containing 1042 natural compounds to identify potential EV-A71 inhibitors. Fangchinoline (FAN), a bis-benzylisoquinoline alkaloid, exhibits potential inhibitory effects against various enteroviruses that cause HFMD, such as EV-A71, CV-A10, CV-B3 and CV-A16. Further investigations revealed that FAN targets the early stage of the enterovirus life cycle. Through the selection of FAN-resistant EV-A71 viruses, we demonstrated that the VP1 protein could be a potential target of FAN, as two mutations in VP1 (E145G and V258I) resulted in viral resistance to FAN. Our research suggests that FAN is an efficient inhibitor of EV-A71 and has the potential to be a broad-spectrum antiviral drug against human enteroviruses.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Publishing services by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qiu-Yan</ForeName><Initials>QY</Initials><AffiliationInfo><Affiliation>The Joint Center of Translational Precision Medicine, Department of Infections and Diseases, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou, 510623, China; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jia-Qi</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>University of Science and Technology of China, Department of Life Sciences and Medicine, Hefei, 230026, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhe-Rui</ForeName><Initials>ZR</Initials><AffiliationInfo><Affiliation>Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao-Dan</ForeName><Initials>XD</Initials><AffiliationInfo><Affiliation>Hunan Normal University, School of Medicine, Changsha, 410081, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hong-Qing</ForeName><Initials>HQ</Initials><AffiliationInfo><Affiliation>Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Cheng-Lin</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Feng-Xia</ForeName><Initials>FX</Initials><AffiliationInfo><Affiliation>The Joint Center of Translational Precision Medicine, Department of Infections and Diseases, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou, 510623, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Joint Center of Translational Precision Medicine, Department of Infections and Diseases, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou, 510623, China. Electronic address: xuyi70@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Joint Center of Translational Precision Medicine, Department of Infections and Diseases, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou, 510623, China; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China. Electronic address: zhangbo@wh.iov.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virol Sin</MedlineTA><NlmUniqueID>101514185</NlmUniqueID><ISSNLinking>1995-820X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044182">Benzylisoquinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>953592C3ZB</RegistryNumber><NameOfSubstance UI="C060802">fangchinoline</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044182" MajorTopicYN="Y">Benzylisoquinolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV-A71</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Fangchinoline (FAN)</Keyword><Keyword MajorTopicYN="N">Hand, foot, and mouth disease (HFMD)</Keyword><Keyword MajorTopicYN="N">High-content screening</Keyword></KeywordList><CoiStatement>Conflict of interest Prof. Bo Zhang is an editorial board member for Virologica Sinica and was not involved in the editorial review or the decision to publish this article. The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>29</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>8</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>7</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38452856</ArticleId><ArticleId IdType="pmc">PMC11074637</ArticleId><ArticleId IdType="doi">10.1016/j.virs.2024.02.006</ArticleId><ArticleId IdType="pii">S1995-820X(24)00026-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arita M., Wakita T., Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J. Gen. Virol. 2008;89:2518–2530.</Citation><ArticleIdList><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaber N., Ramanathan B. Methods in screening antiviral drugs against enterovirus 71. Methods Mol. Biol. 2021;2296:167–184.</Citation><ArticleIdList><ArticleId IdType="pubmed">33977447</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello A.M., Roshorm Y.M. Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD) Biologicals. 2022;79:1–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">36089444</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L., Gao F., Mao Q., Sun S., Wu X., Liu S., Yang X., Liang Z. Hand, foot, and mouth disease associated with coxsackievirus A10: more serious than it seems. Expert Rev. Anti Infect. Ther. 2019;17:233–242.</Citation><ArticleIdList><ArticleId IdType="pubmed">30793637</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra B., Dhingra A.K. Natural products: a lead for drug discovery and development. Phytother. 2021;35:4660–4702.</Citation><ArticleIdList><ArticleId IdType="pubmed">33847440</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C., Li X., Liu S., Xu L., Ye H., Qin C.F., Zhang B. Development and characterization of a clinical strain of Coxsackievirus A16 and an eGFP infectious clone. Virol. Sin. 2015;30:269–276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8200862</ArticleId><ArticleId IdType="pubmed">26220729</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C.L., Yeo H., Ye H.Q., Liu S.Q., Shang B.D., Gong P., Alonso S., Shi P.Y., Zhang B. Inhibition of enterovirus 71 by adenosine analog NITD008. J. Virol. 2014;88:11915–11923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4178731</ArticleId><ArticleId IdType="pubmed">25100827</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong S., Yu R., Wang X., Chen B., Si F., Zhou J., Xie C., Li Z., Zhang D. Bis-benzylisoquinoline alkaloids inhibit porcine epidemic diarrhea virus in vitro and in vivo. Viruses. 2022;14:1231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9228057</ArticleId><ArticleId IdType="pubmed">35746702</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshabrawy H.A., Fan J., Haddad C.S., Ratia K., Broder C.C., Caffrey M., Prabhakar B.S. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay. J. Virol. 2014;88:4353–4365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3993759</ArticleId><ArticleId IdType="pubmed">24501399</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan H., He S.T., Han P., Hong B., Liu K., Li M., Wang S., Tong Y. Cepharanthine: a promising old drug against SARS-CoV-2. Adv. Biol. (Weinh) 2022;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350037</ArticleId><ArticleId IdType="pubmed">35775953</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo B., Su J., Zhang T., Wang K., Li X. Fangchinoline as a kinase inhibitor targets FAK and suppresses FAK-mediated signaling pathway in A549. J. Drug Target. 2015;23:266–274.</Citation><ArticleIdList><ArticleId IdType="pubmed">25539072</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Zhou Y., Lu H., Yang H., Feng Q., Dai Y., Chen L., Yu S., Yao X., Zhang H., Jiang M., Wang Y., Han N., Hu G., He Y. Characterization of severe hand, foot, and mouth disease in Shenzhen, China, 2009-2013. J. Med. Virol. 2015;87:1471–1479.</Citation><ArticleIdList><ArticleId IdType="pubmed">25951788</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka C., Suzuki T., Kotani O., Iwata-Yoshikawa N., Nagata N., Ami Y., Wakita T., Nishimura Y., Shimizu H. The role of VP1 amino acid residue 145 of enterovirus 71 in viral fitness and pathogenesis in a cynomolgus monkey model. PLoS Pathog. 2015;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4504482</ArticleId><ArticleId IdType="pubmed">26181772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D.E., Min J.S., Jang M.S., Lee J.Y., Shin Y.S., Song J.H., Kim H.R., Kim S., Jin Y.H., Kwon S. Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells. Biomolecules. 2019;9:696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6921063</ArticleId><ArticleId IdType="pubmed">31690059</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinobe R., Wiyatno A., Artika I.M., Safari D. Insight into the enterovirus A71: a review. Rev. Med. Virol. 2022;32</Citation><ArticleIdList><ArticleId IdType="pubmed">35510476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K., Sudaka Y., Takashino A., Imura A., Fujii K., Koike S. Amino acid variation at VP1-145 of enterovirus 71 determines attachment receptor usage and neurovirulence in human scavenger receptor B2 transgenic mice. J. Virol. 2018;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052303</ArticleId><ArticleId IdType="pubmed">29848584</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.Q., Deng C.L., Gu D., Li X., Shi L., He J., Zhang Q.Y., Zhang B., Ye H.Q. Development of a replicon cell line-based high throughput antiviral assay for screening inhibitors of Zika virus. Antiviral Res. 2018;150:148–154.</Citation><ArticleIdList><ArticleId IdType="pubmed">29288699</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Maddox C., Rasmussen L., Hobrath J.V., White L.E. Assay development and high-throughput antiviral drug screening against Bluetongue virus. Antiviral Res. 2009;83:267–273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727572</ArticleId><ArticleId IdType="pubmed">19559054</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T., Liu X., Li W. Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy. Oncotarget. 2016;7:40800–40815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5130046</ArticleId><ArticleId IdType="pubmed">27027348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W.W., Kung F.Y., Deng P.A., Lin Y.C., Lin C.W., Kung S.H. Development of a fluorescence resonance energy transfer-based intracellular assay to identify novel enterovirus 71 antivirals. Arch. Virol. 2017;162:713–720.</Citation><ArticleIdList><ArticleId IdType="pubmed">27873071</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins Lima A., Bragina M.E., Burri O., Bortoli Chapalay J., Costa-Fraga F.P., Chambon M., Fraga-Silva R.A., Stergiopulos N. An optimized and validated 384-well plate assay to test platelet function in a high-throughput screening format. Platelets. 2019;30:563–571.</Citation><ArticleIdList><ArticleId IdType="pubmed">30183501</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman D.J., Cragg G.M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 2016;79:629–661.</Citation><ArticleIdList><ArticleId IdType="pubmed">26852623</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y., Lee H., Hafenstein S., Kataoka C., Wakita T., Bergelson J.M., Shimizu H. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog. 2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3723564</ArticleId><ArticleId IdType="pubmed">23935488</ArticleId></ArticleIdList></Reference><Reference><Citation>Saguil A., Kane S.F., Lauters R., Mercado M.G. Hand-foot-and-mouth disease: rapid evidence review. Am. Fam. Physician. 2019;100:408–414.</Citation><ArticleIdList><ArticleId IdType="pubmed">31573162</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai Y., Kolokoltsov A.A., Chen C.C., Tidwell M.W., Bauta W.E., Klugbauer N., Grimm C., Wahl-Schott C., Biel M., Davey R.A. Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science. 2015;347:995–998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550587</ArticleId><ArticleId IdType="pubmed">25722412</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan L., Tong L., Hang L., Fan H. Fangchinoline supplementation attenuates inflammatory markers in experimental rheumatoid arthritis-induced rats. Biomed. Pharmacother. 2019;111:142–150.</Citation><ArticleIdList><ArticleId IdType="pubmed">30579253</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang B., Deng C., Ye H., Xu W., Yuan Z., Shi P.Y., Zhang B. Development and characterization of a stable eGFP enterovirus 71 for antiviral screening. Antivir. Res. 2013;97:198–205.</Citation><ArticleIdList><ArticleId IdType="pubmed">23267829</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma V., Goessling L.S., Brar A.K., Eghtesady P. Multiple subtypes of coxsackievirus group B can cause congenital heart disease. Birth Defects Res. 2023;115:171–178.</Citation><ArticleIdList><ArticleId IdType="pubmed">36094067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulferts R., De Boer S.M., Van Der Linden L., Bauer L., Lyoo H.R., Mate M.J., Lichiere J., Canard B., Lelieveld D., Omta W., Egan D., Coutard B., Van Kuppeveld F.J. Screening of a library of FDA-approved drugs identifies several enterovirus replication inhibitors that target viral protein 2C. Antimicrob. Agents Chemother. 2016;60:2627–2638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4862474</ArticleId><ArticleId IdType="pubmed">26856848</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Z., Lu Y., Liao Q., Wu Y., Chen X. Fangchinoline inhibits human immunodeficiency virus type 1 replication by interfering with gp160 proteolytic processing. PLoS One. 2012;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3374765</ArticleId><ArticleId IdType="pubmed">22720080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.D., Huang J.G., Gao X., Li Y., Zhou S.Y., Yan X., Zou A., Chang J.L., Wang Y.S., Yang G.X., He G.Y. Fangchinoline induced G1/S arrest by modulating expression of p27, PCNA, and cyclin D in human prostate carcinoma cancer PC3 cells and tumor xenograft. Biosci. Biotechnol. Biochem. 2010;74:488–493.</Citation><ArticleIdList><ArticleId IdType="pubmed">20208355</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Liu J., Fang F., Wu J., Ji T., Yang Y., Liu L., Li C., Zhang W., Zhang X., Teng Z. Genomic surveillance of coxsackievirus A10 reveals genetic features and recent appearance of genogroup D in Shanghai, China, 2016-2020. Virol. Sin. 2022;37:177–186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9170976</ArticleId><ArticleId IdType="pubmed">35234621</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi J., Ma C., Wei Z., Yin B., Zhao S., Quan W., Yang J., Yuan J., Qiang B., Ye F., Peng X. A single mutation in the cis-acting replication element identified within the EV-A71 2C-coding region causes defects in virus production in cell culture. Emerg. Microbes Infect. 2021;10:1988–1999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8526025</ArticleId><ArticleId IdType="pubmed">34511027</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Z., Zhang Y., Zhang X., Yang Y., Ma Y., Pang D. Fangchinoline induces G1 arrest in breast cancer cells through cell-cycle regulation. Phytother. Res. 2013;27:1790–1794.</Citation><ArticleIdList><ArticleId IdType="pubmed">23401195</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z., Chen Y.L., Schul W., Wang Q.Y., Gu F., Duraiswamy J., Kondreddi R.R., Niyomrattanakit P., Lakshminarayana S.B., Goh A., Xu H.Y., Liu W., Liu B., Lim J.Y., Ng C.Y., Qing M., Lim C.C., Yip A., Wang G., Chan W.L., Tan H.P., Lin K., Zhang B., Zou G., Bernard K.A., Garrett C., Beltz K., Dong M., Weaver M., He H., Pichota A., Dartois V., Keller T.H., Shi P.Y. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci. U. S. A. 2009;106:20435–20439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787148</ArticleId><ArticleId IdType="pubmed">19918064</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Wang H., Tang J., He Y., Xiong T., Li W., Qu Y., Mu D. Clinical characteristics of severe neonatal enterovirus infection: a systematic review. BMC Pediatr. 2021;21:127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7958388</ArticleId><ArticleId IdType="pubmed">33722228</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., MacDonald N.E., Smith J.C., Cai K., Yu H., Li H., Lei C. Severe enterovirus type 71 nervous system infections in children in the Shanghai region of China: clinical manifestations and implications for prevention and care. Pediatr. Infect. Dis. J. 2014;33:482–487.</Citation><ArticleIdList><ArticleId IdType="pubmed">24732390</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q.Y., Deng C.L., Liu J., Li J.Q., Zhang H.Q., Li N., Zhang Y.N., Li X.D., Zhang B., Xu Y., Ye H.Q. SARS-CoV-2 replicon for high-throughput antiviral screening. J. Gen. Virol. 2021;102</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8295919</ArticleId><ArticleId IdType="pubmed">33956592</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Zhang Y., Li H., Liu L. Hand-foot-and-mouth disease-associated enterovirus and the development of multivalent HFMD vaccines. Int. J. Mol. Sci. 2022;24:169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9820767</ArticleId><ArticleId IdType="pubmed">36613612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Ke X., Zheng C., Liu Y., Xie L., Zheng Z., Wang H. Development of a luciferase-based biosensor to assess enterovirus 71 3C protease activity in living cells. Sci. Rep. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5583365</ArticleId><ArticleId IdType="pubmed">28871120</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Yang E., Hu C., Cheng H., Chen C.Y., Huang D., Wang R., Zhao Y., Rong L., Vignuzzi M., Shen H., Shen L., Chen Z.W. Cell-based high-throughput screening assay identifies 2',2'-difluoro-2'-deoxycytidine gemcitabine as a potential antipoliovirus agent. ACS Infect. Dis. 2017;3:45–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5754216</ArticleId><ArticleId IdType="pubmed">27733043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z.R., Zhang Y.N., Zhang H.Q., Zhang Q.Y., Li N., Li Q., Deng C.L., Zhang B., Li X.D., Ye H.Q. Berbamine hydrochloride potently inhibits SARS-CoV-2 infection by blocking S protein-mediated membrane fusion. PLoS Negl. Trop. Dis. 2022;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9071123</ArticleId><ArticleId IdType="pubmed">35468133</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>